From Breakingviews - Eli Lilly’s golden ticket is a regrettable winner
ever. The pharmaceutical giant is maximizing the diabetes treatment’s gain by using a golden ticket to speed its U.S. approval for use in a possibly bigger market, obesity. Cutting just several months off the approval process could yield $30 billion in additional value. The success doesn't, however, speak to the effectiveness of the government program used to get there.
Almost two decades ago, some Duke University economists noticed pharmaceutical companies avoided developing drugs to cure tropical diseases because the market is small, but the cost and uncertainty of producing them is high. If authorities motivated them with a voucher that allowed them to get to market faster, and the vouchers were transferable, it would incentivize more research and development.
Quicker turnarounds can be worth a lot. Consider a drug that peaks at $1.5 billion in annual revenue. The total gain in present value of product sales from shaving several months off approval time might be $600 million,. About half derives from money arriving sooner, and the rest from additional sales before patent expiration.
Lilly’s peak sales for treating obesity might be about 10 times as high, Jefferies analysts estimate. If the example above is right, that might mean the present value of a faster approval of Mounjaro is $6 billion for Lilly. At the industry multiple of 5 times revenue, that would pad its $535 billion market value by $30 billion. If sales disappoint, or if regulators ultimately say no, it could be worth less.
This disparity between the price of the voucher and the potential value for the buyer is in many ways unique to Mounjaro. It could be a highly effective obesity treatment, the industry’s white whale. Most approved drugs have far more modest sales potential, so a voucher is worth far less.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Eli Lilly's diabetes drug could revolutionize the US weight loss marketEli Lilly’s diabetes drug delivers promising results in a recent clinical trial. The company hopes it will be added to the U.S. weight loss market soon.
Leer más »
The Book Of Eli Ending & Meaning ExplainedThe post-apocalyptic action movie The Book of Eli features a surprise twist ending that leaves audiences with a lot of unanswered questions.
Leer más »
Experimental Drug Slows Alzheimer’s in Large Study, Eli Lilly SaysAn experimental Eli Lilly drug slowed cognitive and functional decline for people with early-stage Alzheimer’s disease in a new study that could support regulatory approval and commercial sale
Leer más »
Eli Lilly's Alzheimer's drug donanemab slows cognitive decline: trialAn experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly
Leer más »
Eli Lilly Alzheimer’s treatment donanemab slowed disease progression in clinical trialDonanemab, a monthly antibody infusion made by pharmaceutical company Eli Lilly, also significantly reduced brain plaque associated with Alzheimer's disease.
Leer más »
Eli Lilly says experimental drug slows Alzheimer's worseningEli Lilly and Co. says its experimental Alzheimer's drug appears to slow worsening of the mind-robbing disease
Leer más »